SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): May 14, 2004
------------
Interleukin Genetics, Inc.
--------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23413 94-3123681
-------------------- ------------------- ----------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation) 94-3123681
135 Beaver Street, Waltham, MA 02452
--------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (781) 398-0700
--------------
Not Applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
1
Item 12. Disclosure of Results of Operations and Financial Condition.
The following exhibits are furnished with this report:
Exhibit Number Description
-------------- ------------
99.1 Press Release dated May 14, 2004
On May 14, 2004, the Registrant issued a press release to report its
financial results for the quarter ended March 31, 2004. A copy of the press
release is attached to this current report on Form 8-K as Exhibit 99.1.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Interleukin Genetics, Inc.
--------------------------
(Registrant)
Date: May 14, 2004 /s/ Fenel M. Eloi
--------------------------
Fenel M. Eloi
Chief Operating Officer,
Chief Financial Officer,
Treasurer and Secretary
3